by Portfolio Grader | February 5, 2014 9:45 am
This week, seven biotechnology stocks are improving their overall rating on Portfolio Grader. Each of these rates an “A” (“strong buy”) or “B” overall (“buy”).
MEI Pharma, Inc. (MEIP) is bumping up its rating from a C (“hold”) to a B (“buy”) this week. For more information, get Portfolio Grader’s complete analysis of MEIP stock.
Biota Pharmaceuticals, Inc. (BOTA) is seeing ratings go up from a C last week to a B this week. For more information, get Portfolio Grader’s complete analysis of BOTA stock.
Northwest Biotherapeutics, Inc. (NWBO) gets a higher grade this week, advancing from a C last week to a B. Northwest Biotherapeutics engages in discovering, developing, and commercializing immunotherapy products to treat cancers in the United States. For more information, get Portfolio Grader’s complete analysis of NWBO stock.
Alexion Pharmaceuticals, Inc. (ALXN) boosts its rating from a C to a B this week. Alexion Pharmaceuticals engages in the innovation, development, and commercialization of life-transforming therapeutic products for treating patients with severe and ultra-rare disorders in the United States, Europe, Latin America, Japan, and the Asia Pacific. Shares of ALXN have increased 19.1% over the past month, better than the 1.3% decrease the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of ALXN stock.
This is a strong week for Emergent BioSolutions Inc. (EBS). The company’s rating climbs to B from the previous week’s C. Emergent BioSolutions develops and produces immunobiotics, pharmaceutical products that assist the body’s immune system to prevent or treat disease. For more information, get Portfolio Grader’s complete analysis of EBS stock.
This week, Cepheid’s (CPHD) ratings are up from a C last week to a B. Cepheid is a molecular diagnostics company that engages in developing, manufacturing, and marketing integrated systems for testing in the clinical market, as well as for application in legacy biothreat, industrial, and partner markets. Wall Street seems to agree with the upgrade and has propelled the stock up 8.8% over the past month. For more information, get Portfolio Grader’s complete analysis of CPHD stock.
This week, Incyte Corporation (INCY) is showing good progress as the company’s rating jumps from a B (“buy”) last week to an A (“strong buy”). Incyte is using its expertise in genomics and medicinal chemistry, as well as molecular, cellular, and in vivo biology to discover and develop novel therapeutics. For more information, get Portfolio Grader’s complete analysis of INCY stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
Source URL: http://investorplace.com/2014/02/7-biotechnology-stocks-to-buy-now-meip-bota-nwbo/
Short URL: http://invstplc.com/1nSK6n6